Correspondence Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force Editor—Following recent articles relating to perioperative antiplatelet drugs (APs) in the British Journal of Anaesthesia, 1–3 we thought it would be of interest to share with you the recommendations of a recent working party in France which addressed the use o...

OBJECTIVE To compare the effectiveness and safety of three types of stents (sirolimus eluting, paclitaxel eluting, and bare metal) in people with and without diabetes mellitus. DESIGN Collaborative network meta-analysis. DATA SOURCES Electronic databases (Medline, Embase, the Cochrane Central Register of Controlled Trials), relevant websites, reference lists, conference abstracts, reviews, ...

BACKGROUND Newer-generation drug-eluting stents that release zotarolimus or everolimus have been shown to be superior to the first-generation drug-eluting stents. However, data comparing long-term safety and efficacy of zotarolimus- (ZES) and everolimus-eluting stents (EES) are limited. RESOLUTE all-comers (Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent fo...

CONTEXT Although drug-eluting stents reduce restenosis rates relative to bare-metal stents, concerns have been raised that drug-eluting stents may also be associated with an increased risk of stent thrombosis. Our study focused on the effect of stent type on population-based interventional outcomes. OBJECTIVE To compare outcomes of Medicare beneficiaries who underwent nonemergent coronary ste...

Two cases of drug-eluting stent restenosis after percutaneous coronary intervention in the left main coronary artery and its bifurcation are presented. An off-pump coronary artery bypass grafting following in-stent restenosis was performed. Drug-eluting stents have shown a reduced frequency of in-stent restenosis and a good safety profile compared with bare metal stents. However, intervention w...

BACKGROUND Previous research suggests that the early benefit from revascularization with drug-eluting stents might diminish over time. METHODS We performed an extended analysis of a previously identified cohort of 6440 patients who underwent percutaneous coronary intervention between April 1, 2003 and March 31, 2005 using a prospective provincial clinical registry in Alberta, Canada. We compa...

BACKGROUND The drug-eluting stents have decreased the incidence of instent restenosis compared to bare metal stents. But, the incidence of late and very late stent thrombosis has increased with the drug-eluting stents. CASE PRESENTATION We are here, reporting three cases of incredibly late instent thrombosis, each one occurring after more than 50 months of drug-eluting stent placement. CONC...

Drug-eluting stents implanted in blood vessels are subject to various dynamics of flow. In this study, we present the evaluation a mathematical model considering effect flow rate, simulate kinetic profiles drug release (Diclofenac Sodium (DS)) from in-vitro PLGA films. This solves set non-linear equation for modeling simultaneously burst, diffusion, swelling and erosion involved mechanisms libe...

BACKGROUND Drug-eluting stents represent a useful strategy for the prevention of restenosis using various antiproliferative drugs. These strategies share the liability of impairing endothelial recovery, thereby altering the natural biology of the vessel wall and increasing the associated risk of stent thrombosis. Accordingly, we tested the hypothesis that local delivery via gene-eluting stent o...

The undisputed superiority of stents over conventional balloon angioplasty has resulted in a plethora of stents in clinical use. Recent data, however, have indicated not all stent models are the same. Nuances in stent design and construction have impacted significantly on the immediate and long-term clinical outcome. Among the stainless steel stents, those with multicellular or tubular designs ...